Investigating high doses of Rifapentine for treating tuberculosis in pregnant women
Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
This study is looking at how to safely treat tuberculosis in pregnant and breastfeeding people, especially those who also have HIV, and it wants to understand what treatment options they and their doctors prefer so that everyone can get the best care possible.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11009318 on NIH RePORTER |
What this research studies
This research focuses on the increased risk of tuberculosis (TB) during and after pregnancy, particularly among those co-infected with HIV. It aims to gather data on the safety and dosing of a new TB treatment regimen for pregnant and breastfeeding individuals, who are often excluded from clinical trials. By using a discrete choice experiment, the study will explore the preferences of pregnant people and healthcare providers regarding TB treatment options. The goal is to ensure that pregnant individuals have access to effective TB treatments that are safe for both them and their developing fetus.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant or breastfeeding individuals who are at risk of or diagnosed with tuberculosis.
Not a fit: Patients who are not pregnant or breastfeeding, or those without a TB diagnosis, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved TB treatment options for pregnant women, reducing mortality and adverse outcomes associated with TB and HIV.
How similar studies have performed: While there is a consensus on the need for including pregnant individuals in TB trials, this specific approach to studying high-dose Rifapentine in this population is relatively novel.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Hirsch-Moverman, Yael R — Columbia University Health Sciences
- Study coordinator: Hirsch-Moverman, Yael R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.